期刊
CELLS
卷 8, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cells8060621
关键词
PDX; breast cancer; humanized mice
类别
资金
- AMED [16 cm0106120h0001, 16ck0106194h0001]
- Japan Society for the Promotion of Science [17K19587, 18H02679]
- Grants-in-Aid for Scientific Research [18H02679, 17K19587] Funding Source: KAKEN
Recently, patient-derived xenograft (PDX) models of many types of tumors including breast cancer have emerged as a powerful tool for predicting drug efficacy and for understanding tumor characteristics. PDXs are established by the direct transfer of human tumors into highly immunodeficient mice and then maintained by passaging from mouse to mouse. The ability of PDX models to maintain the original features of patient tumors and to reflect drug sensitivity has greatly improved both basic and clinical study outcomes. However, current PDX models cannot completely predict drug efficacy because they do not recapitulate the tumor microenvironment of origin, a failure which puts emphasis on the necessity for the development of the next generation PDX models. In this article, we summarize the advantages and limitations of current PDX models and discuss the future directions of this field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据